Traders News Source Identifies four stocks to add to your Watch list Plus Feature Cannabis and Block-chain Report
February 01 2018 - 8:05AM
InvestorsHub NewsWire
February 01, 2018 -- Traders News
Source, a leading independent equity research and corporate access
firm focused on small and mid-cap public companies is issuing a
comprehensive report with no obligation on Agenus Inc.
(NASDAQ:
AGEN), Antares Pharma, Inc. (NASDAQ:
ATRS), Senseonics Holdings, Inc. (NYSE:
SENS), Abraxas Petroleum Corporation (NASDAQ:
AXAS) and or latest research report and comprehensive study on
two of the hottest sectors in the market.
Agenus Inc. (NASDAQ:
AGEN), a clinical-stage immuno-oncology company, focuses on the
discovery and development of therapies that engage the body's
immune system for patients suffering with cancer and develops vaccine programs, such as the Prophage
cancer vaccine. Recently they announced the launch of its Phase 1/2
clinical combination trial with its proprietary anti-CTLA4
(AGEN1884) and anti-PD1 (AGEN2034) antibodies. This two-part trial
is designed to evaluate the safety, tolerability, pharmacokinetics
of the dual drug combination in patients with advanced solid
tumors.
Read our latest comprehensive report on the most promising
Blockchain & Cannabis stocks READ MORE
Copy and paste to your browser may be required to view the
report – https://tradersnewssource.com/mmj-blockchain-report/
Antares Pharma, Inc. (NASDAQ:
ATRS), is developing a new drug, XYOSTED, for the treatment of
testosterone deficiency. They recently announced that a “Type A”
meeting has been scheduled with the U.S. Food and Drug
Administration (FDA) on February 21, 2018 for XYOSTED due to the
“Complete Response Letter” received regarding the New Drug
Application for XYOSTED. Antares Pharma, Inc. is also working with
AMAG Pharmaceuticals on a method for administering Makena, a
product indicated for use in lowering the risk of pre-term
birth.
Senseonics Holdings, Inc. (NYSE:
SENS), a medical technology company focused on the development
of Eversense, a long-term, implantable continuous glucose
monitoring system for people with diabetes for a period of up to 90
days. The company has not received FDA approval yet but is already
selling in Europe. In the U.S. alone, nearly 7 million patients are
on insulin but only a small portion use this kind of therapy and
the consensus Wall Street one-year target is 55% over the current
stock price if they get the anticipated FDA approval.
Get our latest research on some of the most unique Cannabis and
Blockchain stocks READ MORE
Copy and paste to your browser may be required to view the
report – https://tradersnewssource.com/mmj-blockchain-report/
Abraxas Petroleum Corporation (NASDAQ:
AXAS), is an independent energy company that engages in the
acquisition, development, and production of oil and gas properties
in the United States and operates assets in the Permian/Delaware
Basin, the Rocky Mountain, and South Texas regions. They recently
announced that seven wells located in Delaware Basin, Bakken/Three
Forks and Eagle Ford are completed and in full production and will
be producing to targeted expectations. Also with recent
acquisitions and additional identified opportunities at their Bone
Spring/Wolfcamp will allow Abraxas to achieve their goal of over
10,000 net acres. With this latest information Abraxas believes it
will now drill and complete 12 gross and nine operated wells in
2018 instead of their previous assumption or 10 gross and seven net
wells.
FORWARD-LOOKING
DISCLAIMER
This press release may contain
certain forward-looking statements and information, as defined
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, and is subject
to the Safe Harbor created by those sections. This material
contains statements about expected future events and/or financial
results that are forward-looking in nature and subject to risks and
uncertainties. Such forward-looking statements involve risks,
uncertainties and other factors, which may cause the actual
results, performance or achievements of the subject company in this
report to be materially different from the statements made
herein.
COMPLIANCE PROCEDURE
Content is researched, written and
reviewed on a best-effort basis. Information in this release is
fact checked and produced on a best efforts basis. However, we are
only human and are prone to make mistakes. If you notice any errors
or omissions, please notify us below. The subject Company has not
compensated Traders News Source for the creation or dissemination
of this report. Traders News Source is the party responsible for
issuing the press release and for hosting the full analyst report
on Traders News Source website.
NOT FINANCIAL ADVICE
Traders News Source makes no
warranty, expressed or implied, as to the accuracy or completeness
or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to
be construed as personal financial advice. Readers are encouraged
to consult their personal financial advisor before making any
decisions to buy, sell or hold any securities mentioned
herein.
NO WARRANTY OR LIABILITY
ASSUMED
Traders News Source is not
responsible for any error which may be occasioned at the time of
printing of this document or any error, mistake or shortcoming. No
liability is accepted by Traders News Source whatsoever for any
direct, indirect or consequential loss arising from the use of this
document. Traders News Source expressly disclaims any fiduciary
responsibility or liability for any consequences, financial or
otherwise arising from any reliance placed on the information in
this document. Traders News Source does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
Source: Traders News
Source
Contact: editor@tradersnewssource.com